Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib citrate - TWi Biotechnology

Next Previous
Drug Profile

Tofacitinib citrate - TWi Biotechnology

Alternative Names: AC-1101; IMG 003

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TWi Biotechnology
  • Developer ImageneBio; TWi Biotechnology
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis
  • No development reported Granuloma annulare; Vitiligo

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for phase-I development in Granuloma-annulare(In the elderly, In adults) in USA (Topical, Gel)
  • 28 Jul 2025 Ikena Oncology has merged with Inmagene to form ImageneBio
  • 10 Oct 2024 TWi Biotechnology completes a phase I trial in Granuloma annulare (In adults, In the elderly) in USA (Topical) (NCT05580042)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top